Targeting Cardiac Metabolic Pathways: A Role in Ischemic Management

References

• Kaptoge S, Pennells L, De Bacquer D; The WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7:e1332–45. doi:10.1016/S2214-109X(19)30318-3
   PubMed Web of Science ®Google Scholar
• Sakboonyarat B, Rangsin R. Prevalence and associated factors of ischemic heart disease (IHD) among patients with diabetes mellitus: a nationwide, cross-sectional survey. BMC Cardiovasc Disord. 2018;18(151):1–7.
   PubMedGoogle Scholar
• Alexandra N, et al. Mortality from Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019;12(6).
   Web of Science ®Google Scholar
• Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular, Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25. doi:10.1016/j.jacc.2017.04.052
   PubMed Web of Science ®Google Scholar
• Kaski JC, FCrea F, Gersh BJ, Paolo G. Reappraisal of Ischemic Heart Disease. Circulation. 2018;138(14):1463–1480. doi:10.1161/CIRCULATIONAHA.118.031373
   PubMed Web of Science ®Google Scholar
• Pepine J, Wilmer W, Nichols. The pathophysiology of chronic ischemic heart disease. Clin Cardiol. 2007;30(Suppl.I):I-4–I-9. doi:10.1002/clc.20048
   Google Scholar
• Balla C, Pavasini R, Ferrari R. Treatment of angina: where are we? Cardiology. 2018;140(1):52–67. doi:10.1159/000487936
   PubMed Web of Science ®Google Scholar
• Leea L, John H, Michael F.Metabolic manipulation in ischemic heart disease, a novel approach to treatment. Eur Heart J. 2004;25:634–641.
   PubMed Web of Science ®Google Scholar
• Panel M, Ghaleh B, Morin D. Mitochondria and aging: a role for the mitochondrial transition pore? Aging Cell. 2018;1–15.
   Web of Science ®Google Scholar
• Pietrocola F, Lorenzo L, Manuel Bravo-San Pedro J, Madeo F, Kroemer G. Acetyl Coenzyme A: a central metabolite and second messenger. Cell Metab. 2015;21:805–821. doi:10.1016/j.cmet.2015.05.014
   PubMed Web of Science ®Google Scholar
• Fink BN. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res. 2007;73(7):269–277. doi:10.1016/j.cardiores.2006.08.023
   PubMedGoogle Scholar
• Ussher J, Lopaschuk G. The Malonyl CoA axis as a potential target for treating ischemic heart disease. Cardiovasc Res Advan. 2008;79(2):259–268. doi:10.1093/cvr/cvn130
   PubMed Web of Science ®Google Scholar
• Lopaschuk G, et al. Fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207–258. doi:10.1152/physrev.00015.2009
   PubMed Web of Science ®Google Scholar
• Sharpe AJ, McKenzie M. Mitochondrial fatty acid oxidation disorders associated with short-chain Enoyl-CoA Hydratase (ECHS1) deficiency. Cells. 2018;7(46):1–13. doi:10.3390/cells7060046
   Google Scholar
• Agdip S, et al. Optimizing cardiac energy substrate metabolism: a novel therapeutic intervention for ischemic heart disease. Heart Metab. 2008;38:5–14.
   Google Scholar
• Nagoshi T, Yoshimura M, Rosano G, et al. Optimization of cardiac metabolism in heart failure. Curr Pharm Des. 2011;17(35):3846–3853. doi:10.2174/138161211798357773
   PubMed Web of Science ®Google Scholar
• Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J. 2004;25(80):634–641.
   PubMedGoogle Scholar
• Gao Q, Deng H, Li H, et al. Glycolysis and fatty acid β-oxidation, which one is the culprit of ischemic reperfusion injury? Int J Clin Exp Med. 2018;11(1):59–68.
   Web of Science ®Google Scholar
• Karwi OG, Uddin GM, Ho KL, Lopaschuk GD. Loss of metabolic flexibility in the failing heart. Front Cardiovasc Med. 2018;5(68):1–13. doi:10.3389/fcvm.2018.00068
   PubMedGoogle Scholar
• Lopaschuk GD. Metabolic changes in the acutely ischemic heart. Heart Metab. 2016;70:32–35.
   Google Scholar
• Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. Cardiovasc Res. 2011;90:202–209. doi:10.1093/cvr/cvr038
   PubMed Web of Science ®Google Scholar
• Folmes C, Sowah D, Clanachan A, Lopaschuk G. High rates of residual fatty acid oxidation during mild ischemia decrease cardiac work and efficiency. J Mol Cell Cardiol. 2009;47:142–148. doi:10.1016/j.yjmcc.2009.03.005
   PubMed Web of Science ®Google Scholar
• Natasha Fillmore N, Lopaschuk GD. Malonyl CoA: a promising target for the treatment of cardiac disease. 2014. Int Union Biochem Mol Biol. 2014;66(3):139–146.
   Google Scholar
• Pauly D, Pipen J. Ischemic heart disease: metabolic approaches to management. Clin Cardiol. 2004;27:439–444. doi:10.1002/clc.4960270802
   PubMed Web of Science ®Google Scholar
• Horváth, Horváth B, Hézső T, et al. Late sodium current inhibitors as potential antiarrhythmic agents. Front Pharmacol. 2020;11(413):1–17. doi:10.3389/fphar.2020.00413
   PubMedGoogle Scholar
• Kuntz MJ, Harris RA. Pyruvate Dehydrogenase Kinase. In: Choi S, editor. Encyclopedia of Signaling Molecules. New York, NY: Springer; 2018. https://doi.org/10.1007/978-1-4614-6438-9_101636-2.
   Google Scholar
• Richard C. Partial Fatty Acid Oxidation (pFOX) inhibition: a new therapy for chronic stable angina. Clin Cardiol. 2003;26:161–162. doi:10.1002/clc.4960260402
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904–910. doi:10.1161/01.CIR.0000139333.83620.5D
   PubMed Web of Science ®Google Scholar
• Podbregar M, Voga G. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J Card Fail. 2002;8:369–378. doi:10.1054/jcaf.2002.130238
   PubMed Web of Science ®Google Scholar
• Teitelbaum J. Enhancing Mitochondrial Function with D-Ribose. Integrative Med. 2008;7:2.
   Google Scholar
• Mamas MA, Neyses L, Fath-Ordoubadi F, et al. A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction. Exp Clin Cardiol. 2010;15:2.
   Google Scholar
• Vlasselaers D. Gluco-insulin-potassium: much more than enriched myocardial fuel. Circulation. 2011;123(2):129–130. doi:10.1161/CIRCULATIONAHA.110.002709
   PubMed Web of Science ®Google Scholar
• Vander Horst J, Zijlstra F, Van’t Hof AWJ. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction (GIPS): a randomized trial. J Am Coll Cardiol. 2003;42:784–791. doi:10.1016/S0735-1097(03)00830-1
   PubMedGoogle Scholar
• Legtenberg R, Houston R, Oeseburg B, Smits P. Physiological insulin concentrations protect against ischemia-induced loss of cardiac function in rats. Comp Biochem Physiol Mol Integr Physiol. 2002;132:161–167. doi:10.1016/S1095-6433(01)00543-8
   PubMed Web of Science ®Google Scholar
• Ahmed W, et al. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation. J Int Med. 2007;262(2):184–198. doi:10.1111/j.1365-2796.2007.01825.x
   PubMed Web of Science ®Google Scholar
• Abdelrahman M, Sivarajah A, Thiemermann C, et al. Beneficial effects of PPAR-g ligands in ischemia–reperfusion injury, inflammation and shock. Cardiovasc Res. 2005;65:772–778. doi:10.1016/j.cardiores.2004.12.008
   PubMed Web of Science ®Google Scholar
• Desvergne B, Michalik L, Wahli W. Transcriptional regulation of metabolism. Physiol Rev. 2006;86:465–514. doi:10.1152/physrev.00025.2005
   PubMed Web of Science ®Google Scholar
• Yue, W Bao, BM Jucker, et al. Activation of peroxisome proliferator–activated receptor-protects the heart from ischemia/reperfusion injury. Circulation. 2003;11.
   Google Scholar
• Huang JV, Greyson CR, Schwartz GG. PPAR-as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res. 2012;53.
   Web of Science ®Google Scholar
• EFSA Panel on Dietetic Products. Scientific opinion on dietary reference values for niacin. EFSA J. 2014;12(7):3759. doi:10.2903/j.efsa.2014.3759
   Google Scholar
• Markel A, et al. The resurgence of niacin: from nicotinic acid to niaspan/laropiprant. IMAJ. 2011;13.
   Google Scholar
• Carlso L. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258:94–114. doi:10.1111/j.1365-2796.2005.01528.x
   PubMed Web of Science ®Google Scholar
• Sang J, Weon K. Mechanism of ischemia and reperfusion injury to the heart: from the viewpoint of nitric oxide and mitochondria. Chonnam Med J. 2010;46(3):129–139. doi:10.4068/cmj.2010.46.3.129
   Google Scholar
• Patel BP, Rawal UM, Dave TK, et al. Lipid peroxidation, total antioxidant status and total thiol levels predict overall survival in patients with oral squamous cell carcinoma. Invest Cancer Ther. 2007;6(4):365–372. doi:10.1177/1534735407309760
   PubMed Web of Science ®Google Scholar
• Soares, Soares ROS, Losada DM, et al. Ischemia/reperfusion injury revisited: an overview of the latest pharmacological strategies. Int J Mol Sci. 2019;20(5034):1–45. doi:10.3390/ijms20205034
   Google Scholar
• Nojiri S, Daida H, Mokuno H. Association of serum antioxidant capacity with coronary artery disease in middle-aged men. Heart J. 2001;42:677–690.
   Google Scholar
• Wimmer NJ, Stone PH. Anti-anginal and anti-ischemic effects of late sodium current inhibition. Cardiovasc Drugs Ther. 2013;27(1):69–77. doi:10.1007/s10557-012-6431-z
   PubMed Web of Science ®Google Scholar
• Ramachandra CJA, Hernandez-Resendiz S, Crespo-Avilan GE, et al. Mitochondria in acute myocardial infarction and cardioprotection. EBioMedicine. 2020;57(2020):102884. doi:10.1016/j.ebiom.2020.102884
   PubMedGoogle Scholar
• Nan J, Zhu W, Rahman MS, et al. Molecular regulation of mitochondrial dynamics in cardiac disease. Biochim Biophys Acta. 2017;1864:1260–1273. doi:10.1016/j.bbamcr.2017.03.006
   Web of Science ®Google Scholar
• Boyman L, Karbowski M, Lederer WJ. Regulation of mitochondrial ATP production: ca2+ signaling and quality control. Trends Mol Med. 2020;2020(26):21–39. doi:10.1016/j.molmed.2019.10.007
   Google Scholar
• Wang J, Zhou H. Mitochondrial quality control mechanisms as molecular targets in cardiac ischemia-reperfusion injury. Acta Pharm Sin B. 2020. doi:10.1016/j.apsb.2020.03.004
   Web of Science ®Google Scholar
• Fu W, Liu Y, Yin H. Mitochondrial dynamics: biogenesis, fission, fusion, and mitophagy in the regulation of stem cell behaviors. Hindawi. 2019;2019(9757201):1–15.
   Google Scholar
• Maneechote C, Siripong Palee S, Chattipakorn SC, Chattipakorn N. Roles of mitochondrial dynamics modulators in cardiac ischaemia/reperfusion injury. J Cell Mol Med. 2017;21(11):2643–2653. doi:10.1111/jcmm.13330
   PubMed Web of Science ®Google Scholar
• Carreira RS, Lee P, Gottlieb RA. Mitochondrial therapeutics for cardioprotection. Curr Pharm Des. 2011;17(20):2017–2035. doi:10.2174/138161211796904777
   PubMed Web of Science ®Google Scholar
• Gao D, Zhang L, Dhillon R, et al. Dynasore protects mitochondria and improves cardiac lusitropy in Langendorff perfused mouse heart. PLoS One. 2013;8:e60967. doi:10.1371/journal.pone.0060967
   PubMed Web of Science ®Google Scholar
• Disatnik MH, Ferreira JC, Campos JC, et al. Acute inhibition of excessive mitochondrial fission after myocardial infarction prevents long-term cardiac dysfunction. J Am Heart Assoc. 2013;2:e000461. doi:10.1161/JAHA.113.000461
   PubMed Web of Science ®Google Scholar
• Sharp WW, Fang YH, Han M, et al. Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission. FASEB J. 2014;28:316–326. doi:10.1096/fj.12-226225
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Lambert JP, Nicholson CK, et al. DJ-1 protects the heart against ischemia-reperfusion injury by regulating mitochondrial fission. J Mol Cell Cardiol. 2016;97:56–66. doi:10.1016/j.yjmcc.2016.04.008
   PubMed Web of Science ®Google Scholar
• Ong SB, Subrayan S, Lim SY, et al. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 2010;121:2012–2022. doi:10.1161/CIRCULATIONAHA.109.906610
   PubMed Web of Science ®Google Scholar
• Din S, Mason M, Volkers M, et al. Pim-1 preserves mitochondrial morphology by inhibiting dynamin-related protein 1 translocation. Proc Natl Acad Sci USA. 2013;110:5969–5974. doi:10.1073/pnas.1213294110
   PubMed Web of Science ®Google Scholar
• Hall AR, Burke N, Dongworth RK, et al. Hearts deficient in both Mfn1 and Mfn2 are protected against acute myocardial infarction. Cell Death Dis. 2016;7:e2238. doi:10.1038/cddis.2016.139
   PubMed Web of Science ®Google Scholar
• Yang Y, Li T, Li Z, Liu N, Yan Y, Liu B. Role of mitophagy in cardiovascular disease. Aging Dis. 2020;11(2):419–437. doi:10.14336/AD.2019.0518
   PubMed Web of Science ®Google Scholar
• Redmann M, Dodson M, Boyer-Guittaut M, Darley-Usmar V, Zhang J. Mitophagy mechanisms and role in human diseases. Int J Biochem Cell Biol. 2014;53:127–133. doi:10.1016/j.biocel.2014.05.010
   PubMed Web of Science ®Google Scholar
• Guzy RD, Schumacker PT. O_2 sensing by mitochondria at complex III: the paradox of increased reactive O_2 species during hypoxia. Exp Physiol. 2006;91:807–819. doi:10.1113/expphysiol.2006.033506
   PubMed Web of Science ®Google Scholar
• Chu D, Zhang Z. Trichosanthis pericarpium aqueous extract protects H9c2 Cardiomyocytes from Hypoxia/ReO_2ation Injury by Regulating PI3K/Akt/NO pathway. Molecules. 2018;23:2409. doi:10.3390/molecules23102409
   PubMed Web of Science ®Google Scholar
• Yuan, Yuan X, Juan Z, et al. Clemastine fumarate protects against myocardial ischemia reperfusion injury by Activating the TLR4/PI3K/Akt signaling pathway. Front Pharmacol. 2020;11:28. doi:10.3389/fphar.2020.00028
   PubMed Web of Science ®Google Scholar
• Zhang, Zhang L, Li Y, et al. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol Cancer. 2020;19(1):10. doi:10.1186/s12943-019-1112-1
   PubMed Web of Science ®Google Scholar
• Gang S, Sun G, Liu H, Shu L, Zhang W, Liang Z. Prokineticin 2 relieves hypoxia/reO_2ation-induced injury through activation of Akt/mTOR pathway in H9c2 cardiomyocytes. Artif Cells Nanomed Biotechnol. 2020;48:345–352. doi:10.1080/21691401.2019.1709850
   PubMed Web of Science ®Google Scholar
• Hill BG, et al. Bioenergetics and translational metabolism: implications for genetics. Physiol Prec Med Biol Chem. 2020;401(1):3–29.
   Google Scholar
• Nadtochiy SM, Schafer X, Fu D, Nehrke K, Munger J, Brookes PS. Acidic pH is a metabolic switch for 2-hydroxyglutarate generation and signaling. J Biol Chem. 2016;291:20188–20197. doi:10.1074/jbc.M116.738799
   PubMed Web of Science ®Google Scholar
• Rzem R, Achouri Y, Marbaix E, et al. A mouse model of L-2-hydroxyglutaric aciduria, a disorder of metabolite repair. PLoS One. 2015;10:e0119540. doi:10.1371/journal.pone.0119540
   PubMed Web of Science ®Google Scholar
• Fessel JP, Oldham WM. Pyridine dinucleotides from molecules to man. Antioxid Redox Signal. 2018;28:180–212. doi:10.1089/ars.2017.7120
   PubMed Web of Science ®Google Scholar
• Husted AS, Trauelsen M, Rudenko O, Hjorth SA, Schwartz TW. GPCR-mediated signaling of metabolites. Cell Metab. 2017;25:777–796. doi:10.1016/j.cmet.2017.03.008
   PubMed Web of Science ®Google Scholar